(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Incyte's revenue in 2025 is $4,413,226,000.On average, 9 Wall Street analysts forecast INCY's revenue for 2025 to be $905,319,999,940, with the lowest INCY revenue forecast at $893,818,655,172, and the highest INCY revenue forecast at $931,162,360,409. On average, 9 Wall Street analysts forecast INCY's revenue for 2026 to be $1,000,200,625,930, with the lowest INCY revenue forecast at $942,727,970,396, and the highest INCY revenue forecast at $1,066,204,489,165.
In 2027, INCY is forecast to generate $1,089,227,503,545 in revenue, with the lowest revenue forecast at $1,031,832,275,984 and the highest revenue forecast at $1,226,515,237,105.